Key result
Elevated troponin predicts left ventricular dysfunction and cardiotoxicity during cancer therapy.
Why the study?
Further evidence was required regarding troponin and brain natriuretic peptide assessment as screening tests to predict cardiotoxicity and identify cancer patients needing cardio-oncology referral.
Does the assessment of troponin and brain natriuretic peptide levels predict cardiotoxicity in cancer patients receiving cancer therapy?
Does the assessment of troponin and brain natriuretic peptide levels predict cardiotoxicity in cancer patients receiving cancer therapy?
Elevated troponin levels can predict LV dysfunction in cancer patients, suggesting its potential utility as a screening tool to identify patients needing cardio-oncology referral and preventive strategies.
Answers are grounded in this paper and cite their sources.
Supports troponin monitoring to guide cardio-oncology referral during cancer therapy; confirms predictive value across studies.
Elevated troponin levels predict LV dysfunction in patients receiving cancer therapy. Assessment of troponin levels may qualify as a screening test to identify patients who require referral to cardio-oncology units and benefit from preventive strategies. Further evidence is required for both biomarkers.
No takes yet. Share an insight, caveat, or question.
Michel et al. (2019) studied this question. Elevated troponin levels predict left ventricular dysfunction in patients receiving cancer therapy and may serve as a screening tool for cardiotoxicity.
Synapse has enriched 10 related papers. Consider them for comparative context: